Project Grant R01AG090773
Award Date
12/15/24
Completion Date
11/30/29
Dollars Obligated
$751K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
The National Institute on Aging (NIA), under its Aging Research program (CFDA 93.866), has awarded a $2,112,826 cooperative agreement to the University of California, San Diego (UCSD) to advance a CRISPR-based therapeutic for Alzheimer's disease (AD) towards pre-IND stage. The project aims to determine the optimal gene-editing combination to edit the APP gene, which plays a central role in AD pathogenesis, and shift the APP cleavage pathway from pathologic to physiologic. UCSD will evaluate...
The National Institutes of Health's National Institute on Aging awarded a $7,432,562 project grant to the Regents of the University of California, San Francisco on September 15, 2022 under the Aging Research program (CFDA 93.866). The grant will support research to elucidate the roles of Alzheimer's disease risk genes and variants in gene expression and AD-related phenotypes through 2025.
Specifically, the University of California, San Francisco will use CRISPR and single-cell RNA sequencing...
This Project Grant award from the National Institute on Aging (CFDA 93.866, Aging Research) provides $919,106 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research aimed at discovering and optimizing small molecules that can "correct" the function of the Alzheimer's disease risk factor APOE4 to be more similar to the lower-risk APOE3 variant.
The key products and services to be delivered under this 5-year grant include developing a novel high-throughput...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $433,824 to the J. David Gladstone Institutes in San Francisco, CA to investigate how the Alzheimer's disease risk factor APOE4 disrupts the maturation and integration of adult-born dentate granule cells in the hippocampus. The research aims to elucidate the underlying transcriptomic changes and electrophysiological alterations that lead to hyperexcitability in these neurons, with the...
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $4,694,672 to North Dakota State University from May 15, 2021 through April 30, 2024. The funding supports research to design a non-viral gene delivery system for delivering an APOE2 plasmid to the brain. Specifically, the university will synthesize and characterize liposomal nanoparticles loaded with chitosan-APOE2 polyplexes and modified with transferrin and cell-penetrating...
The National Institute on Aging (NIA) awarded a $619,681 Project Grant (CFDA 93.866 - Aging Research) to The Leland Stanford Junior University to develop a toolkit called Combo-Seq/Tag. This toolkit combines precise gene editing to install multiple Alzheimer's disease (AD) risk alleles (Combo-Seq) with a multiplex protein tagging tool (Combo-Tag) to study endogenous protein interactions. The project aims to enable efficient perturbation of AD risk genes and multi-omics readouts in human stem...
The University of North Carolina at Chapel Hill (UNC-CH) received a $424,095 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to develop a CRISPR/Cas13 gene therapy targeting the tau protein for the treatment of Alzheimer's disease and other tauopathies. The project aims to identify and validate optimal guide RNAs to deplete specific tau isoforms in neurons, and evaluate the therapeutic potential of this approach in preclinical Alzheimer's disease mouse...
This federal Project Grant award, valued at $728,406.00 and administered by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), supports research to identify transcription factors that regulate the expression of the MAPT gene, which is associated with neurodegenerative diseases like Alzheimer's.
The key objectives are to: (1) use CRISPR screens to find transcription factors that can modulate MAPT transcription, (2) determine which trans-regulatory elements...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $573,788.00 to the Baylor College of Medicine to develop a high-throughput in vivo CRISPR/Cas9 screening method to identify regulators of tau protein levels in mouse models of Alzheimer's disease. The goal is to bypass labor-intensive in vitro processes and directly identify brain-specific therapeutic targets for neurodegenerative diseases involving toxic protein accumulation. This 2-year...